DOCSLIB.ORG

New Frontiers

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
New Frontiers PROGRAM & BOOK OF ABSTRACTS JUNE 13-16, 2009 • PORTLAND, OREGON New Frontiers Children’s Tumor FoundaTION 95 PINE STREET, 16TH FLOOR, NEW YORK, NY 10005 | WWW.CTF.ORG | 212.344.6633 Dear NF Conference Attendees: On behalf of the Children’s Tumor Foundation, welcome to the 2009 NF Conference: New Frontiers. The theme references the meeting content and also Portland itself, historically a gateway port of the Pacific North West. The urban setting offers a ‘new frontier’ in comparison to the mountain and beach locales of past NF Conferences, but one which we feel you will enjoy. Portland is an easy-going city offering history, beauty and relaxation – features encapsulated in our host hotel The Nines, itself a part of the tapestry of Portland history, renovated from the former landmark Meier & Frank department store. The last year has seen major NF research advances. The dovetailing of discovery, translation and the clinic can be seen throughout the meeting. We are firmly in the age of NF clinical trials and proud that the Children’s Tumor Foundation is part of this advance: in 2009 we funded our first two pilot Clinical Trial Awards. We continue to build a pipeline of candidate NF drug therapies through the Foundation’s multi-center NF Preclinical Consortium and the seed grant Drug Discovery Initiative (DDI) program. Through these translational initiatives we are cultivating NF collaborations with the biotechnology and pharmaceutical sector, a critical factor in moving NF research forward to the clinic. At the same time, basic research advances continue, such as in the unraveling of schwannomatosis. Through our Schwannomatosis Awards program, the Foundation has committed around $500,000 to schwannomatosis since INI-1 was identified as a candidate gene in 2007. This includes discovery research, genesis of schwannomatosis mouse models and now, establishing a Schwannomatosis Natural History Database. Underpinning the bench-to-bedside pathway is the Foundation’s NF Clinic Network, now 38 Affiliate Clinics in the United States and growing. NFCN strives to improve NF clinical care and to build bridges with the NF patient community. In planning is the addition of an NF BioBank and Patient Registry, to facilitate researcher access to NF tissue and clinical data, and empower NF patients to participate in accelerating NF research to the clinic. We still face many frontiers on the road to ending neurofibromatosis, but let’s celebrate the path we have carved so far. Enjoy the meeting! Sincerely, Kim Hunter-Schaedle, Ph.D. John W. Risner Chief Scientific Officer President CONTENTS Table of Contents INTRODUCTION Research Programs of the Children’s Tumor Foundation .....................................5 Foundation Staff at the 2009 NF Conference .......................................................6 Children’s Tumor Foundation National Programs .................................................7 CME Credits - NYU Welcome Letter and Course Description ................................10 INFORMATION Schedule At-A-Glance ........................................................................................16 Important Notes To Chairs, Speakers & Poster Presenters ...................................17 Vote For Your Favorite Posters ............................................................................18 Schedule ...........................................................................................................19 ABSTRACTS Keynote Presentations .......................................................................................27 Session 1: NF Clinical Trials Updates ..................................................................29 Session 2: Correlating NF Phenotype and Genotype ............................................33 Session 3A: Clinical Features of NF ....................................................................35 Session 3B: Molecular Basis of Tumors in NF .....................................................37 Session 4A: NF1 in Context: A View of Related Ras-MAPK Disorders ...................40 Session 4B: Basic - Unraveling the Signaling Pathways of NF ..............................43 Session 5B: Basic - Unraveling the Signaling Pathways of NF (cont.) ...................46 Session 6: Recent Advances in Understanding NF1 Cognitive Deficits ..................48 Session 7: NF2 and Schwannomatosis: What’s New? .........................................50 Session 8A: Novel Cellular and Animal Models of NF ...........................................53 Session 8B: Progress in Management of NF1 Bone Abnormalities .......................56 Session 9: NF Therapeutic Targets and Preclinical Drug Screening .......................60 POSTERS Poster Presentation: Session 1 (odd numbers) ...................................................63 Poster Presentation: Session 2 (even numbers) ..................................................83 APPENDIX Attendees List - 2009 NF Conference .................................................................103 Maps ................................................................................................................106 4 | Children’s Tumor Foundation • Ending Neurofibromatosis Through Research RESEARCH PROGRAMS Research Programs of the Children’s Tumor Foundation The Children’s Tumor Foundation is dedicated to ending neurofibromatosis (NF) through research. For over 25 years, Research Programs of the Children’s Tumor Foundation .....................................5 the Foundation has funded NF research with the goal of identifying NF drug therapies and improving the lives of those Foundation Staff at the 2009 NF Conference .......................................................6 living with the disorder. To date, the Foundation has committed over $30M to NF research initiatives. The Foundation also provides resources for NF patients and their families, and endeavors to increase public awareness of NF. Children’s Tumor Foundation National Programs .................................................7 CME Credits - NYU Welcome Letter and Course Description ................................10 The Foundation has been a long-time key advocate for federal support of NF research. The Foundation works closely with the National Institutes of Health and has been instrumental in the inception and continuation of the United States Schedule At-A-Glance ........................................................................................16 Army’s Congressionally Directed Medical Research Program. Important Notes To Chairs, Speakers & Poster Presenters ...................................17 Vote For Your Favorite Posters ............................................................................18 The research programs of the Children’s Tumor Foundation support discovery and translational research, clinical trials and clinical care. Schedule ...........................................................................................................19 Keynote Presentations .......................................................................................27 Open Programs: Call for Applications Session 1: NF Clinical Trials Updates ..................................................................29 • Young Investigator Awards: Our longest running research program provides two year grants for pre- and post- Session 2: Correlating NF Phenotype and Genotype ............................................33 doctoral researchers in NF research. YIA continues as a cornerstone program of the Foundation. Many of today’s Session 3A: Clinical Features of NF ....................................................................35 NF community leaders are former YIA recipients. Next deadline: early 2010. Session 3B: Molecular Basis of Tumors in NF .....................................................37 • Drug Discovery Initiative Awards: Grants of up to $50,000 for pilot preclinical drug screening. To date, this Session 4A: NF1 in Context: A View of Related Ras-MAPK Disorders ...................40 program has funded 25 drug screens. Multiple deadlines: see www.ctf.org. Session 4B: Basic - Unraveling the Signaling Pathways of NF ..............................43 • Clinical Trial Awards: Offer $125,000 to conduct small-scale pilot clinical trials of candidate NF therapeutics. Session 5B: Basic - Unraveling the Signaling Pathways of NF (cont.) ...................46 Deadline: Letter of Intent required. Contact the Foundation first. Session 6: Recent Advances in Understanding NF1 Cognitive Deficits ..................48 • NF Clinic Network (CTF-NFCN): Recognizes those clinics offering comprehensive NF clinical care. Session 7: NF2 and Schwannomatosis: What’s New? .........................................50 Now 38 Affiliate Clinics. Any clinic may apply for participation. U.S. Clinics eligible to receive seed funding to Session 8A: Novel Cellular and Animal Models of NF ...........................................53 expand clinic activities. Deadlines: February 28th and August 31st. Session 8B: Progress in Management of NF1 Bone Abnormalities .......................56 Session 9: NF Therapeutic Targets and Preclinical Drug Screening .......................60 Ongoing Programs (no current call for applications) • The NF Preclinical Consortium: part of a $5M effort to advance NF research in the clinics. Research teams at six Poster Presentation: Session 1 (odd numbers) ...................................................63 centers collaborating in screening the most promising candidate NF therapeutics in multiple
Load more

Recommended publications
  • Teri Melese, Ph.D
    Prepared: 02/015 University of California, San Diego Curriculum Vitae Name: Teri Melese, Ph.D Current Position: UCSD Assistant Vice Chancellor, Industry Research Alliances Adjunct Associate Professor, Department of Medicine and Rady School of Management Last Position Held: Adjunct Associate Professor UCSF Department of Medicine, School of Medicine, 2005-2012 UCSF Dean’s Office: Director of Business Strategy and Development, School of Medicine UCSF Helen Diller Comprehensive Cancer Center Executive Committee: Associate Director for Strategic Alliances Address: University of California, San Diego Office of Research Affairs 9500 Gilman Drive #0910 La Jolla, CA 92093-0043 Tel: (858) 822-5247 mobile: (408) 373-3651 [email protected] Education: 1975-77 University of California, Berkeley A.B. Neurobiology/ Literature 1977-82 University of California, San Francisco Ph.D. Regents Fellow 1982-86 University of California, Los Angeles Postdoctoral Fellow Biochemistry 1986-87 University of California, Los Angeles American Cancer Sr. Research Fellow Molecular Biology Principal Positions Held: 1988-92 Columbia University, New York Assistant Professor Biological Sciences 1993-97 Columbia University, New York Associate Professor Biological Sciences 1997-99 Columbia University, New York Adjunct Associate Professor Biological Sciences 1997-01 Iconix Pharmaceuticals Mountain View Founding Member & Director Chemical Genomics 2001-2012 University of California, San Francisco Adjunct Full Professor Step II Medicine Present University of California, San Diego
    [Show full text]
  • Molecular Chaperones in Cancer
    CNIO - SPANISH”LA CAIXA”NATIONAL CANCER FOUNDATION RESEARCH CENTRE FRONTIERS MEETINGS 2017 Madrid 2nd- 4th May 2017 MOLECULAR CHAPERONES IN CANCER IN MEMORY OF SUSAN LINDQUIST Organisers Nabil Djouder Spanish National Cancer Research Centre (CNIO), Madrid, Spain Wilhelm Krek Institute for Molecular Health Sciences Zurich, Switzerland Paul Workman The Institute of Cancer Research London, UK Xiaohong Helena Yang Cancer Cell Cambridge, US EXCELENCIA MINISTERIO DE ECONOMÍA, INDUSTRIA SEVERO Y COMPETITIVIDAD OCHOA CNIO - SPANISH”LA CAIXA”NATIONAL CANCER FOUNDATION RESEARCH CENTRE FRONTIERS MEETINGS 2017 Madrid 2nd- 4th May 2017 MOLECULAR CHAPERONES IN CANCER CNIO - SPANISH”LA CAIXA”NATIONAL CANCER FOUNDATION RESEARCH CENTRE FRONTIERS MEETINGS 2017 Madrid 2nd- 4th May 2017 MOLECULAR CHAPERONES IN CANCER Summary 07 PROGRAMME 19 KEYNOTE LECTURE 23 SESSIONS 23 S #1 PROTEIN QUALITY CONTROL 31 S #2 FOLDING, MISFOLDING AND AGGREGATION 41 S #3 STRESS MECHANISMS IN CANCER 49 S #4 CHAPERONES IN CANCER 59 S #5 TARGETING CHAPERONES: CHAPERONOTHERAPY 67 CLOSING LECTURE 69 ORGANISERS AND SPEAKERS’ BIOGRAPHIES 99 POSTER SESSIONS 119 Previous CNIO Frontiers Meetings and CNIO Cancer Conferences 05 CNIO - SPANISH”LA CAIXA”NATIONAL CANCER FOUNDATION RESEARCH CENTRE FRONTIERS MEETINGS 2017 Madrid 2nd- 4th May 2017 MOLECULAR CHAPERONES IN CANCER PROGRAMME 07 PROGRAMME Madrid 2nd- 4th May 2017 MOLECULAR CHAPERONES IN CANCER Venue: Spanish National Cancer Research Centre – CNIO Auditorium, Madrid, Spain Chairpersons and organizing committee: Nabil Djouder, Spanish National Cancer Research Centre, Madrid, Spain Wilhelm Krek, Institute for Molecular Health Sciences, ETH, Zurich, Switzerland Paul Workman, The Institute of Cancer Research, London, UK Xiaohong Helena Yang, Cancer Cell, Cambridge, USA Rationale: Molecular chaperones play key roles in the folding, stability and activity of proteins in normal cell homeostasis and disease pa- thology, including cancer.
    [Show full text]
  • The Olympics and Economics 2012 Contents
    The Olympics and Economics 2012 Contents The Olympics and Economics 2012 .......................................................................................................................................... 1 Interview with Michael Johnson ............................................................................................................................................ 2 (Sprinter, four-time Olympic gold medallist and world record holder) Impact on the UK: 2012 Olympics Likely to Provide Economic As Well As Sporting Benefits ..................................... 4 Interview with Matthew Syed .................................................................................................................................................. 6 (Journalist, author and table tennis champion and a two-time Olympian) Gold Goes Where Growth Environment Is Best—Using Our GES to Predict Olympic Medals .................................... 8 Interview with Tim Hollingsworth ......................................................................................................................................... 12 (Chief Executive of the British Paralympic Association) Summer Olympics and Local House Prices: The Cases of Los Angeles and Atlanta ................................................... 14 The Olympics as a Winning FX Strategy ............................................................................................................................... 16 Impact of Olympics on Stock Markets ..................................................................................................................................
    [Show full text]
  • New Frontiers
    PROGRAM & BOOK OF ABSTRACTS JUNE 13-16, 2009 • PORTLAND, OREGON New Frontiers Children’s Tumor FoundaTION 95 PINE STREET, 16TH FLOOR, NEW YORK, NY 10005 | WWW.CTF.ORG | 212.344.6633 Dear NF Conference Attendees: On behalf of the Children’s Tumor Foundation, welcome to the 2009 NF Conference: New Frontiers. The theme references the meeting content and also Portland itself, historically a gateway port of the Pacific North West. The urban setting offers a ‘new frontier’ in comparison to the mountain and beach locales of past NF Conferences, but one which we feel you will enjoy. Portland is an easy-going city offering history, beauty and relaxation – features encapsulated in our host hotel The Nines, itself a part of the tapestry of Portland history, renovated from the former landmark Meier & Frank department store. The last year has seen major NF research advances. The dovetailing of discovery, translation and the clinic can be seen throughout the meeting. We are firmly in the age of NF clinical trials and proud that the Children’s Tumor Foundation is part of this advance: in 2009 we funded our first two pilot Clinical Trial Awards. We continue to build a pipeline of candidate NF drug therapies through the Foundation’s multi-center NF Preclinical Consortium and the seed grant Drug Discovery Initiative (DDI) program. Through these translational initiatives we are cultivating NF collaborations with the biotechnology and pharmaceutical sector, a critical factor in moving NF research forward to the clinic. At the same time, basic research advances continue, such as in the unraveling of schwannomatosis.
    [Show full text]
  • Registrant List (23)
    State/Cou nty/Provin Zip (Postal First Name Last Name Company Address Line 1 Address Line 2 City US State ce Code) Country Work Phone Attendee Email Address Ibrahim Abaidalla University of Missouri E2509 Lafferre Hall Columbia Missouri USA 65201 United States (573) 529-2695 [email protected] Stony Brook Sherif Abdelaziz Stony Brook University 2424 Computer Science Bldg University Stony Brook New York 11794-4424 United States 6316329341 [email protected] Craig Abney Cajun Deep Foundations, LLC 15635 Airline Hwy Baton Rouge Louisiana 70817 United States 2257541369 [email protected] 8901 John Carpenter Freeway, Tim Abrams Terracon Consultants, Inc. Suite 100 Dallas Texas 75247 United States 214-630-1010 [email protected] Mike Abruzzo Richard Goettle, Inc. 12071 Hamilton Avenue CINCINNATI Ohio 45231 United States 5138258100 [email protected] Murad Abufarsakh Louisiana State University 13048 Quail Meadow Drive Baton Rouge Louisiana 70817 United States 2257679147 [email protected] Moe Accinno American Equipment & Fabricating / SOILMEC 100 Water Street East Providence Rhode Island 02914 United States 401-438-2626 [email protected] EUSEBIO ACENERO LEON AGINTECO CONSULTING SIERRA GUADARRAMA, 37 MADRID 28830 Spain 34695383142 [email protected] Fernando Ache Bay Shore Systems, Inc. 14206 N. Ohio Street Rathdrum Idaho 83858 United States 2086873311 [email protected] KOFI ACHEAMPONG KCI Technologies, Inc. 936 Ridgebrook Road Sparks Maryland 21152 United States 410-316-7888 [email protected] Grant Achey Arthur R. Henry Inc. 3031 Ocean Heights Ave Egg HArbor Twp New Jersey 08234 United States 6099276660 [email protected] andrew.ackerman@nicholsonconstru Andrew Ackerman Nicholson Construction Company 2400 Ansys Drive, Suite 303 Canonsburg Pennsylvania 15317 United States 412-221-4500 ction.com Jaime Acuna TEI Rock Drills Inc.
    [Show full text]
  • Alumni Data Points Important?
    0 | Page TABLE OF CONTENTS ABSTRACT .................................................................................................................. 2 OVERVIEW ................................................................................................................... 3 RAISER’S EDGE DATABASE ..................................................................................... 5 CURRENT ATTRIBUTES ............................................................................................. 7 RECOMMENDED DATA POINTS .............................................................................. 17 ADDED DATA POINTS .................................................................................... 17 REMOVED/CLEANED DATA POINTS ............................................................. 22 IMPORTED DATA TYPES .......................................................................................... 24 UT DALLAS CAREER CENTER (COMET CAREERS) .................................... 24 ORGSYNC ....................................................................................................... 25 ORION APPLICANTCENTER & STUDENT CENTER ..................................... 26 APPLYTEXAS.ORG ......................................................................................... 27 IMPORTING DATA INTO CONSTITUENT RECORDS .............................................. 28 IMPORTING NEW RECORDS ......................................................................... 28 UPDATING EXISTING RECORDS .................................................................
    [Show full text]
  • LONG-TERM MEMBERS 25+ Years of Membership
    LONG-TERM MEMBERS 25+ Years of Membership Stuart A. Aaronson, MD Stephen P. Ackland, MBBS Carol Aghajanian, MD Steven A. Akman, MD Icahn School of Medicine at Mount Sinai University of Newcastle Memorial Sloan Kettering Cancer Center Roper St. Francis Healthcare United States Australia United States United States Active Member Active Member Active Member Active Member 38 Years of Membership 33 Years of Membership 27 Years of Membership 35 Years of Membership Cory Abate-Shen, PhD Edward M. Acton, PhD Irina U. Agoulnik, PhD Emmanuel T. Akporiaye, PhD Columbia University Irving Medical United States Florida International University Verana Therapeutics Center Emeritus Member United States United States United States 42 Years of Membership Active Member Emeritus Member Active Member 25 Years of Membership 31 Years of Membership 26 Years of Membership David J. Adams, PhD Duke University Medical Center Imran Ahmad, PhD Ala-Eddin Al Moustafa, PhD James L. Abbruzzese, MD United States Northwestern Medicine McGill University Duke University Emeritus Member United States Canada United States 32 Years of Membership Active Member Active Member Active Member 25 Years of Membership 26 Years of Membership 32 Years of Membership Gregory P. Adams, PhD Elucida Oncology Nihal Ahmad, PhD Abdul Al Saadi, PhD Ehtesham A. Abdi, MBBS United States Univ. of Wisconsin Madison Sch. of Med. William Beaumont Hospital The Tweed Hospital Active Member & Public Health United States Australia 29 Years of Membership United States Emeritus Member Emeritus Member Active Member 52 Years of Membership 33 Years of Membership Lucile L. Adams-Campbell, PhD 25 Years of Membership Georgetown Lombardi Comprehensive Suresh K.
    [Show full text]
  • Assemblée Nationale - Autres Subventions
    Assemblée nationale - Autres subventions Montant versés Programme Député(e), groupe ou Département de Nom du bénéficiaire Nature de la subvention en 2013 (en €) budgétaire Présidence mandat 100% sport et loisirs 1 000 € NC 219 CINIERI Dino 42 - Loire 1686° Section des Médaillés Militaires 1 000 € Fonctionnement 169 SORDI Michel 68 - Haut-Rhin Meyenheim quartier Dio 35th « Santa Fe » Division in Normandy 1 500 € Fonctionnement 169 GOSSELIN Philippe 50 - Manche Matériel studios musique, salles de danse et 37è parallèle 14 000 € 224 GILLE Jean-Patrick 37 - Indre-et-Loire d'atelier 4Chem1 Evolution 4 000 € Soutien scolaire de jeunes en difficulté 230 GUIGOU Elisabeth 93 - Seine-Saint-Denis 4H Tarare 1 000 € NC 219 VERCHERE Patrice 69 - Rhône 55ème section Bar-le-Duc de la Sté nationale 1 000 € Achat d'un nouveau drapeau 169 CINIERI Dino 42 - Loire d'entraide de la médaille militaire A chacun ses vacances 3 000 € Fonctionnement 157 FILLON François 75 - Paris A coeur Joie 1 000 € Fonctionnement 224 PERRUT Bernard 69 - Rhône A P E L Ecole Saint Joseph 1 000 € Fonctionnement 214 MARC Alain 12 - Aveyron A petits pas 2 000 € Fonctionnement 140 HEINRICH Michel 88 - Vosges A Portée de Voix 1 000 € Fonctionnement 224 DE LA RAUDIERE Laure 28 - Eure-et-Loir A portée de Voix 3 000 € Fonctionnement 224 SOLERE Thierry 92 - Hauts-de-Seine A Travers Chant 1 000 € Fonctionnement 224 STRAUMANN Eric 68 - Haut-Rhin A votre Service 1 000 € Fonctionnement 106 LAZARO Thierry 59 - Nord A.A.S.D.A.F 2 000 € Fonctionnement 214 GERARD Bernard 59 - Nord A.B.C.
    [Show full text]
  • Sprawozdanie 2018 2.Pdf
    1 2 SPRAWOZDANIE Z DZIAŁALNOŚCI INSTYTUTU ZA ROK 2018 Opracowano w Dziale Zarządzania Wiedzą Łódź, 2019 3 4 Spis treści I. O INSTYTUCIE .................................................................................................................... 9 1. Struktura organizacyjna (według stanu na dzień 31.12.2018 r.) ................................................. 9 2. Rada Naukowa (wg stanu na dzień 31.12.2018 r.) .................................................................... 14 3. Kadra (wg stanu na dzień 31.12.2018 r.) ................................................................................... 21 II. STRUKTURA ZADAŃ ......................................................................................................... 27 1. Główne kierunki badawcze ....................................................................................................... 27 2. Realizacja zadań według podstawowych źródeł finansowania ................................................. 28 3. Komisja Bioetyczna .................................................................................................................... 30 III. OSIĄGNIĘCIA W ZAKRESIE DZIAŁALNOŚCI NAUKOWO-BADAWCZEJ .................................. 33 1. Potencjał naukowy .................................................................................................................... 33 a. Uprawnienia do nadawania stopni naukowych .................................................................... 33 b. Rozwój kadry naukowej ........................................................................................................
    [Show full text]
  • This Electronic Thesis Or Dissertation Has Been Downloaded from Explore Bristol Research
    This electronic thesis or dissertation has been downloaded from Explore Bristol Research, http://research-information.bristol.ac.uk Author: Marcolino De Assis Junior, Eudmar Title: The regulation of PRH/HHEX by transforming growth factor General rights Access to the thesis is subject to the Creative Commons Attribution - NonCommercial-No Derivatives 4.0 International Public License. A copy of this may be found at https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode This license sets out your rights and the restrictions that apply to your access to the thesis so it is important you read this before proceeding. Take down policy Some pages of this thesis may have been removed for copyright restrictions prior to having it been deposited in Explore Bristol Research. However, if you have discovered material within the thesis that you consider to be unlawful e.g. breaches of copyright (either yours or that of a third party) or any other law, including but not limited to those relating to patent, trademark, confidentiality, data protection, obscenity, defamation, libel, then please contact [email protected] and include the following information in your message: •Your contact details •Bibliographic details for the item, including a URL •An outline nature of the complaint Your claim will be investigated and, where appropriate, the item in question will be removed from public view as soon as possible. The regulation of PRH/HHEX by transforming growth factor β By Eudmar Marcolino de Assis Junior A thesis submitted to the University of Bristol, School of Biochemistry, for the degree of Doctor of Philosophy Word count: 56,442 ABSTRACT The transcription factor PRH/HHEX (Proline-Rich Homeodomain/Haematopoietically Expressed Homeobox) controls cell proliferation, cell differentiation and cell migration/invasion in a diverse range of cell types.
    [Show full text]
  • Recommendations for the Echocardiographic Assessment of Native Valvular Regurgitation: an Executive Summary from the European Association of Cardiovascular Imaging
    European Heart Journal – Cardiovascular Imaging (2013) 14, 611–644 RECOMMENDATIONS doi:10.1093/ehjci/jet105 Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging Patrizio Lancellotti1*, Christophe Tribouilloy2, Andreas Hagendorff3, Downloaded from Bogdan A. Popescu4, Thor Edvardsen5, Luc A. Pierard1, Luigi Badano6, and Jose L. Zamorano7, On behalf of the Scientific Document Committee of the European Association of Cardiovascular Imaging: Thor Edvardsen, Oliver Bruder, Bernard Cosyns, Erwan Donal, Raluca Dulgheru, Maurizio Galderisi, Patrizio http://ehjcimaging.oxfordjournals.org/ Lancellotti, Denisa Muraru, Koen Nieman, Rosa Sicari, Document reviewers: Erwan Donal, Kristina Haugaa, Giovanni La Canna, Julien Magne, Edyta Plonska 1Department of Cardiology, GIGA Cardiovascular Sciences, University of Lie`ge Hospital, Valvular Disease Clinic, CHU Sart Tilman, Lie`ge 4000, Belgium; 2Department of Cardiology, University Hospital of Amiens, Picardie, France; 3Department fu¨r Innere Medizin, Kardiologie, Leipzig, Germany; 4Euroecolab, ‘Carol Davila’ University of Medicine and Pharmacy, Institute of Cardiovascular Diseases, Bucharest, Romania; 5Department of Cardiology and Center for Cardiological Innovation, Oslo University Hospital, Rikshospitalet and University of Oslo, Oslo, Norway; 6Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy; and 7University Hospital Ramo´n y Cajal, Madrid, Spain Received 7 May 2013; accepted after revision 12 May 2013 at ESC Member (EHJCI) on June 14, 2013 Valvular regurgitation represents an important cause of cardiovascular morbidity and mortality. Echocardiography has become the primary non- invasive imaging method for the evaluation of valvular regurgitation. The echocardiographic assessment of valvular regurgitation should integrate the quantification of the regurgitation, assessment of the valve anatomy and function, as well as the consequences of valvular disease on cardiac chambers.
    [Show full text]
  • Acknowledgment of Reviewers, 2016
    Acknowledgment of Reviewers, 2016 The PNAS editors would like to thank all the individuals who dedicated their considerable time and expertise to the journal by serving as reviewers in 2016. Their generous contribution is deeply appreciated. A Lia Addadi Edoardo Airoldi Kathleen A. Alexander Rommie E. Amaro Lauri A. Aaltonen Nii Addy Joanna Aizenberg R. Wayne Alexander Richard M. Amasino Duur K. Aanen Karen Adelman Javier Aizpurua Emil Alexov Stanley H. Ambrose Jorge D. Abad Neil Adger Caroline M. Michael Alfaro Andre L. B. Ambrosio Adam R. Abate Sankar Adhya Ajo-Franklin Juan D. Alfonzo Indu S. Ambudkar Cory Abate-Shen Claire L. Adida Myles Akabas Thomas J. Algeo Amal Amer Abul K. Abbas Becky Adkins Arne N. Akbar Hashim M. Al-Hashimi Daniel L. Ames Jessica Lee Abbate Jess F. Adkins Omar S. Akbari Nageeb Ali Daniel R. Ames Jonathan Abbatt Carrie Adler Erol Akcay Robin R. Ali James B. Ames Elio A. Abbondanzieri Frederick R. Adler Cezmi Akdis Karen Alim Céline Amiez Dorian S. Abbot Ralph Adolphs Mark Akeson A. Paul Alivisatos Sebastian Amigorena Geoffrey W. Abbott Markus Aebi Joshua M. Akey Michael T. Alkire Ariel Amir Karen C. Abbott Philippe V. Afonso Anna Akhmanova Suvarna Alladi David M. Amodio Larry F. Abbott Arash Afraz Ethan Akin Brian F. Allan L. Mario Amzel Nicholas L. Abbott Hervé Agaisse Deji Akinwande David Alland Gynheung An Rasha Abdel Rahman Dritan Agalliu Shizuo Akira Jun Allard Li An Jeffrey N. Agar Irit Akirav Andrew E. Allen Omar Abdel-Wahab Weihua An Ritesh Agarwal Aleksei Aksimentiev Charles N. Allen Jintanat Ananaworanich Ikuro Abe Neus Agell Dag L.
    [Show full text]